Aerie Pharmaceuticals Reports Third Quarter 2013 Financial Results and Provides Business and Product Development Update
12/04/2013
Aerie Successfully Completes Initial Public Offering
Proceeding with Clinical Trials for Highly Differentiated Glaucoma Products
Conference Call and Webcast Today,
Aerie Highlights
-
Closed its initial public offering (IPO) on
October 30, 2013 , generating gross proceeds of$77.3 million , and$68.3 million after IPO fees and expenses. As ofNovember 30, 2013 , Aerie had approximately$70.5 million of cash on its balance sheet. - Proceeds are expected to fund AR-13324 Phase 3 development through NDA filing currently forecasted in the first half of 2016, and PG324 development through expected completion of its Phase 2b trial in the summer of 2014 and including subsequent follow-on Phase 3 preparatory activities.
- All product candidates are internally developed with patent protection through at least 2030 in the U.S., and all rights are retained by Aerie.
"Aerie made significant progress in 2013, capped off with our successful
IPO which provides the capital for us to continue to fund development of
our highly differentiated product portfolio," said
Product Development Update
Aerie's first-in-class product candidates are all single drop, once-daily dosing, are well tolerated and have shown no systemic drug-related adverse events.
Dual-Action AR-13324
AR-13324 has a novel dual-action mechanism of action (MOA) that we believe, if approved, would render this product the only once-daily drug available that specifically targets the trabecular meshwork (TM), the eye's primary fluid drain and the diseased tissue responsible for elevated intraocular pressure (IOP) in glaucoma. We believe AR-13324, which increases TM drainage through Rho Kinase (ROCK) inhibition, will also be the first glaucoma drug to inhibit norepinephrine transporter (NET), a second mechanism which reduces fluid production in the eye. In addition, we believe the AR-13324 dual-action MOA is highly complementary to the mechanism of the leading prostaglandin analogues (PGAs), which increase fluid outflow through a secondary drainage pathway in the eye.
In our Phase 2b clinical trial, which was successfully completed in
AR-13324 is being prepared for two Phase 3 registration trials that are expected to commence in mid-2014, with total expected enrollment of approximately 1,200 patients. The trials will measure efficacy over three months and safety over 12 months. The primary efficacy endpoint of the trials will be to demonstrate non-inferiority of IOP lowering for AR-13324 (dosed once daily) compared to timolol (dosed twice daily). Timolol is the most widely used comparator in registration trials for glaucoma, and is also the most widely prescribed add-on therapy to PGAs.
Assuming we commence the trials on schedule, three-month efficacy results are expected to be released in mid-2015, and if the trials are successful, we expect to submit our NDA filing in the first half of 2016.
Triple-Action PG324
PG324 is a once-daily eye drop that combines our dual-action compound AR-13324 with latanoprost, a prostaglandin analogue that is the most widely prescribed glaucoma drug. If approved, we believe that PG324 would be the first glaucoma product to lower IOP through all three MOAs: increasing fluid outflow through the TM or primary drain, increasing fluid outflow through the uveoscleral pathway or secondary drain, and reducing fluid production in the eye. We believe that PG324, if approved, would be the only glaucoma product that covers the full spectrum of IOP-lowering mechanisms, thereby providing a greater IOP-lowering effect than any currently approved glaucoma product.
Triple-action PG324 has been tested in a preclinical primate model, and
the results of a three-day study demonstrated that at all time points,
PG324 dosed once daily reduced IOP substantially more than latanoprost
alone dosed once daily. In addition, Aerie has established human proof
of concept with previous ROCK inhibitor /
This product candidate is being prepared for a 28-day Phase 2b clinical trial that is expected to commence with first patient treated early in the first quarter of 2014. The study is expected to include approximately 300 patients and will compare two concentrations of PG324 to latanoprost and to AR-13324, all dosed once daily. The efficacy endpoint will be superiority of PG324 to each of its components. Results of the Phase 2b trial are currently expected in mid-2014.
Financial Results
The Company's initial public offering closed on
The Company reported a net loss attributable to common stockholders as
measured in accordance with U.S. generally accepted accounting
principles ("GAAP") for the quarter ended
The
The
The
The
Conference Call / Web Cast Information
Aerie management will host a live conference call and webcast at
The live webcast and a replay may be accessed by visiting Aerie's
website at http://investors.aeriepharma.com.
Please connect to the Company's website at least 15 minutes prior to the
live webcast to ensure adequate time for any software download that may
be needed to access the webcast. Alternatively, please call (888)
734-0328 (U.S.) or (678) 894-3054 (international) to listen to the live
conference call. The conference ID number for the live call is 10045249.
Please dial in approximately 10 minutes prior to the call. Telephone
replay will be available approximately two hours after the call. To
access the replay, please call (855)-859-2056 (U.S.) or (404) 537-3406
(international). The conference ID number for the replay is 10045249.
The telephone replay will be available until
About
Aerie is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies. The Company is preparing for two Phase 3 registration trials where the primary efficacy endpoint will be to demonstrate non-inferiority of IOP lowering for AR-13324 (dosed once daily) compared to timolol (dosed twice daily). The Company is also preparing for a Phase 2b clinical trial where the primary efficacy endpoint will be to demonstrate superiority of PG324 to each of its components.
Forward-Looking Statements
This press release contains forward-looking statements for purposes of
the safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. We may, in some cases, use terms such as "predicts,"
"believes," "potential," "continue," "estimates," "anticipates,"
"expects," "plans," "intends," "may," "could," "might," "will," "should"
or other words that convey uncertainty of future events or outcomes to
identify these forward-looking statements. Forward-looking statements
include statements regarding our intentions, beliefs, projections,
outlook, analyses or current expectations concerning, among other
things: the success, timing and cost of our ongoing clinical trials and
anticipated Phase 3 and Phase 2b clinical trials for our current product
candidates, including statements regarding the timing of initiation and
completion of the trials; the timing of and our ability to obtain and
maintain
Non-GAAP Financial Measures
To supplement our financial statements, which are prepared and presented in accordance with GAAP, we use the following non-GAAP financial measures, some of which are discussed above: adjusted net income (loss), adjusted operating expenses, adjusted research and development expenses, adjusted general and administrative expenses, and adjusted other income (expense). For a description of the adjusted calculations and reconciliation to the nearest GAAP measure, please see the "Reconciliation of GAAP Net Loss to Adjusted Net Loss" table in this press release.
We believe these non-GAAP financial measures provide investors with useful supplemental information about the financial performance of our business, enable comparison of financial results between periods where certain items may vary independent of business performance, and allow for greater transparency with respect to key metrics used by management in operating our business.
The presentation of these financial measures is not intended to be considered in isolation from, or as a substitute for, financial information prepared and presented in accordance with GAAP. Investors are cautioned that there are material limitations associated with the use of non-GAAP financial measures as an analytical tool. In particular, the adjustments to our GAAP financial measures reflect the exclusion of stock compensation expense, which is recurring and will be reflected in our financial results for the foreseeable future. In addition, these measures may be different from non-GAAP financial measures used by other companies, limiting their usefulness for comparison purposes. We compensate for these limitations by providing specific information regarding the GAAP amounts excluded from these non-GAAP financial measures.
|
(A Development Stage Company) Balance Sheets (in thousands, except share and per share data) |
||||||||
|
2013 |
2012 |
|||||||
| (unaudited) | ||||||||
| Assets | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | 4,619 | $ | 2,925 | ||||
| Prepaid expenses and other current assets | 117 | 113 | ||||||
| Deferred offering costs | 2,330 | — | ||||||
| Total current assets | 7,066 | 3,038 | ||||||
| Furniture, fixtures and equipment, net | 114 | 133 | ||||||
| Other assets, net | 62 | 48 | ||||||
| Total assets | $ | 7,242 | $ | 3,219 | ||||
| Liabilities, Convertible Preferred Stock and Stockholders' Deficit | ||||||||
| Current liabilities | ||||||||
| Accounts payable and other current liabilities | $ | 3,175 | $ | 1,437 | ||||
| Notes payable, net of discount—related parties | 14,433 | 2,331 | ||||||
| Interest payable—related parties | 504 | 16 | ||||||
| Total current liabilities | 18,112 | 3,784 | ||||||
| Warrants liability—related parties | 11,485 | 2,456 | ||||||
| Total liabilities | 29,597 | 6,240 | ||||||
| Commitments and contingencies | ||||||||
|
Convertible preferred stock, |
||||||||
|
Series A-1—2,000,000 shares authorized as of |
1,000 | 1,000 | ||||||
|
Series A-2—10,010,029 shares authorized as of |
10,000 | 10,000 | ||||||
|
Series A-3—22,479,476 shares authorized as of |
20,979 | 20,979 | ||||||
|
Series A-4—5,683,404 shares authorized as of |
4,826 | 4,606 | ||||||
|
Series B—47,700,000 shares authorized as of |
24,506 | 24,313 | ||||||
| Total convertible preferred stock | 61,311 | 60,898 | ||||||
| Stockholders' deficit | ||||||||
|
Common stock, |
1 | 1 | ||||||
| Additional paid-in capital | 1,123 | 4 | ||||||
| Deficit accumulated during the development stage | (84,790 | ) | (63,924 | ) | ||||
| Total stockholders' deficit | (83,666 | ) | (63,919 | ) | ||||
| Total liabilities, convertible preferred stock and stockholders' deficit | $ | 7,242 | $ | 3,219 | ||||
|
(A Development Stage Company) Statements of Operations and Comprehensive Loss (Unaudited) (in thousands, except share and per share data) |
||||||||||||||||||||
|
Three Months Ended |
Nine Months Ended |
Period From
Inception ( 2005) to |
||||||||||||||||||
| 2013 | 2012 | 2013 | 2012 |
2013 |
||||||||||||||||
| Operating expenses | ||||||||||||||||||||
| General and administrative | $ | (3,287) | $ | (1,416) | $ | (6,693) | $ | (3,701) | $ | (26,590) | ||||||||||
| Research and development | (2,399) | (1,373) | (8,727) | (7,305) | (51,876) | |||||||||||||||
| Loss from operations | (5,686) | (2,789 | ) | (15,420 | ) | (11,006 | ) | (78,466) | ||||||||||||
| Other income (expense) -— net | (5,062) | (803) | (5,446 | ) | (427) | (6,188) | ||||||||||||||
| Net loss | $ | (10,748 | ) | $ | (3,592 | ) | $ | (20,866 | ) | $ | (11,433 | ) | $ | (84,654 | ) | |||||
| Comprehensive loss | $ | (10,748 | ) | $ | (3,592 | ) | $ | (20,866 | ) | $ | (11,433 | ) | $ | (84,654 | ) | |||||
| Net loss attributable to common stockholders — basic and diluted | $ | (10,887 | ) | $ | (3,730 | ) | $ | (21,279 | ) | $ | (11,845 | ) | ||||||||
| Net loss per share attributable to common stockholders — basic and diluted | $ | (10.81 | ) | $ | (3.87 | ) | $ | (21.61 | ) | $ | (12.38 | ) | ||||||||
| Weighted average number of common shares outstanding — basic and diluted | 1,006,893 | 964,880 | 984,727 | 957,079 | ||||||||||||||||
|
|
||||||||||||||||
| Reconciliation of GAAP Net Loss to Adjusted Net Loss | ||||||||||||||||
| (In thousands) | ||||||||||||||||
| (Unaudited) | ||||||||||||||||
|
Three Months Ended |
Nine Months
Ended |
|||||||||||||||
|
|
|
|||||||||||||||
| 2013 | 2012 | 2013 | 2012 | |||||||||||||
| Net loss attributable to common stockholders — basic and diluted: | ||||||||||||||||
| Net loss attributable to common stockholders — basic and diluted (GAAP) | $ | (10,887 | ) | $ | (3,730 | ) | $ | (21,279 | ) | $ | (11,845 | ) | ||||
| Adjustments: | ||||||||||||||||
| Stock-based compensation (a) | 1,130 | 108 | 1,531 | 292 | ||||||||||||
| Change in fair value measurements of warrant liabilities (b) | 3,585 | 788 | 3,850 | 441 | ||||||||||||
| Accrued interest and amortization expense related to notes subsequently converted to common equity (c) | 1,477 | — | 2,865 | — | ||||||||||||
| Accretion related to convertible preferred stock (d) | 139 | 138 | 413 | 412 | ||||||||||||
| Adjusted Net income (loss) | $ | (4,556 | ) | $ | (2,696 | ) | $ | (12,620 | ) | $ | (10,700 | ) | ||||
| Operating expenses: | ||||||||||||||||
| General and administrative expense: | ||||||||||||||||
| General and administrative expense (GAAP) | $ | (3,287 | ) | $ | (1,416 | ) | $ | (6,693 | ) | $ | (3,701 | ) | ||||
| Adjustments: | ||||||||||||||||
| Stock-based compensation (a) | 1,068 | 86 | 1,426 | 226 | ||||||||||||
| Adjusted general and administrative expense | $ | (2,219 | ) | $ | (1,330 | ) | $ | (5,267 | ) | $ | (3,475 | ) | ||||
| Research and development expense: | ||||||||||||||||
| Research and development expense (GAAP) | $ | (2,399 | ) | $ | (1,373 | ) | $ | (8,727 | ) | $ | (7,305 | ) | ||||
| Adjustments: | ||||||||||||||||
| Stock-based compensation (a) | 62 | 22 | 105 | 66 | ||||||||||||
| Adjusted research and development expense | $ | (2,337 | ) | $ | (1,351 | ) | $ | (8,622 | ) | $ | (7,239 | ) | ||||
| Operating expenses (GAAP) | $ | (5,686 | ) | $ | (2,789 | ) | $ | (15,420 | ) | $ | (11,006 | ) | ||||
| Adjustments: | ||||||||||||||||
| Stock-based compensation (a) | 1,130 | 108 | 1,531 | 292 | ||||||||||||
| Adjusted operating expenses | $ | (4,556 | ) | $ | (2,681 | ) | $ | (13,889 | ) | $ | (10,714 | ) | ||||
| Other income (expense): | ||||||||||||||||
| Other income (expense) (GAAP) | $ | (5,062 | ) | $ | (803 | ) | $ | (5,446 | ) | $ | (427 | ) | ||||
| Adjustments: | ||||||||||||||||
| Change in fair value measurements of warrant liabilities (b) | 3,585 | 788 | 3,850 | 441 | ||||||||||||
| Accrued interest and amortization expense related to notes subsequently converted to common equity (c) | 1,477 | — | 2,865 | — | ||||||||||||
| Adjusted other income (expense) | $ | 0 | $ | (15 | ) | $ | 1,269 | $ | 14 | |||||||
Aerie is providing adjusted information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors' understanding of the Company's performance. This information should be considered in addition to, but not in lieu of, information prepared in accordance with GAAP.
Explanation of adjustments:
(a) Stock-based compensation: Exclude
the non-cash stock-based compensation.
(b) Change in fair value
measurements of warrant liabilities: Exclude the non-cash
change in fair value.
(c) Accrued interest and amortization
expense related to notes subsequently converted to common equity: Exclude
the non-cash interest and amortization expense.
(d) Accretion
related to convertible preferred stock: Exclude the accretion
related to convertible preferred stock.
rrubino@aeriepharma.com
or
akolhatkar@burnsmc.com
Source:
News Provided by Acquire Media
